

Research Article

Synthesis of *N*-(2-chloro-5-methylthiophenyl)-*N'*-(3-methyl-thiophenyl)-*N'*-[³H₃]methylguanidine, {[³H₃]CNS-5161}

Andrew R. Gibbs^{1,*}, Hiromi Morimoto², Henry F. VanBrocklin¹, Philip G. Williams² and Anat Biegon¹

¹ *Department of Functional Imaging, Lawrence Berkeley National Laboratory, 1 Cyclotron Road MS 55-121, Berkeley, CA 94720, USA*

² *National Tritium Labeling Facility, Lawrence Berkeley National Laboratory, 1 Cyclotron Road MS 75-123, Berkeley, CA 94720, USA*

Summary

The preparation of the title compound, [³H₃]CNS-5161, was accomplished in three steps starting with the production of [³H₃]iodomethane (CT₃I). The intermediate *N*-[³H₃]methyl-3-(thiomethylphenyl)cyanamide was prepared in 77% yield by the addition of CT₃I to 3-(thiomethylphenyl)cyanamide, previously treated with sodium hydride. Reaction of this tritiated intermediate with 2-chloro-5-thiomethylaniline hydrochloride formed the guanidine compound [³H₃]CNS-5161. Purification by HPLC gave the desired labeled product in an overall yield of 9% with >96% radiochemical purity and a final specific activity of 66 Ci mmol⁻¹. Copyright © 2002 John Wiley & Sons, Ltd.

Key Words: CNS-5161; tritium; NMDA

*Correspondence to: A. R. Gibbs, Department of Functional Imaging, Lawrence Berkeley National Laboratory, 1 Cyclotron Road MS 55-121, Berkeley, CA 94720, USA.
E-mail: ARGibbs@lbl.gov

Contract/grant sponsor: Director of Lawrence Berkeley National Laboratory
Contract/grant sponsor: US Department of Energy; contract/grant number: DE-AC03-76SF00098
Contract/grant sponsor: US National Institutes of Health; contract/grant number: P41 RR01237

Copyright © 2002 John Wiley & Sons, Ltd.

Received 22 October 2001
Accepted 21 November 2001

Introduction

Glutamate, the major excitatory neurotransmitter in the brain, is thought to be involved in normal memory formation and brain plasticity as well as in pathological states such as stroke, head injury, epilepsy and several neurodegenerative and psychiatric disorders.¹⁻⁷ Glutamate interacts with several receptors, but a key role has been ascribed to the NMDA receptor, which is a ligand-gated ion (calcium) channel. Binding of glutamate to its binding site on the extracellular side of the transmembrane structure results in channel opening and influx of calcium into the cell. Glycine is a required cofactor. Noncompetitive antagonists (e.g., PCP, MK-801, CERESTAT; Figure 1) for the receptor have been identified and are thought to be 'use dependent' ligands (i.e. they bind to a site inside the channel when the receptor is activated by glutamate).⁸ Therefore, increases in binding of agents of this class could be direct indicators of excessive glutamate release in the brain, a process implicated in excitotoxic neuronal death following brain ischemia. Excitotoxicity has also been suggested to contribute to neuronal death in neurodegenerative disorders such as Alzheimer's and Parkinson's diseases.^{1,3,4,7} Due to its perceived importance in numerous crucial physiological and pathological states, this receptor/channel has been the target of intensive research efforts aimed, among other things, at developing an appropriate radioligand for imaging of this receptor *in vivo*. Most of these efforts have not met with success.⁹⁻¹² In search of novel structures with promising attributes for *in vivo* imaging, we chose





Figure 1. NMDA receptor non-competitive antagonists

CNS-5161, a compound with high affinity and selectivity to the NMDA receptor channel,¹³ as a candidate for tritium labeling and further characterization.

Results and discussion

The preparation of **3**, [³H₃]CNS-5161, was accomplished in two steps by the pathway shown in Scheme 1, an adaptation of the synthesis described by Hu *et al.*¹³ The major change to the original synthesis minimized the use of halogenated solvents thereby limiting the amount of mixed radioactive waste produced.

The intermediate *N*-[³H₃]methyl-3-(thiomethylphenyl)cyanamide **2** was achieved by the addition of tritiated iodomethane^{14,15} to 3-(thiomethylphenyl)cyanamide **1**, previously treated with sodium hydride. Excess non-radioactive iodomethane was added to the reaction to force the methylation to completeness, eliminating the need to chromatographically purify **2**. This process, however, reduced the specific activity from near theoretical 85 to 66 Ci mmol⁻¹. The yield for this reaction was nearly 77% with the unreacted CT₃I being removed during the evaporation process. Reaction of **2** with 2-chloro-5-thiomethylaniline hydrochloride provided the guanidine compound [³H₃]CNS-5161, **3**. A 5–6-fold stoichiometric excess of 2-chloro-5-thiomethylaniline hydrochloride was found to be necessary for guanidine formation. Purification through two HPLC columns gave **3** with a final specific activity of 66 Ci mmol⁻¹ and >96% radiochemical purity. The yield for this reaction was ~12%. The final product was stored at a concentration of 1 mCi ml⁻¹ in ethanol at -18°C. Ten per cent radiolytic decomposition was noted over a period of ~9 months of storage.



Scheme 1. Preparation of [³H₃]CNS-5161

Conclusion

The modified two-step reaction sequence produced the desired tritiated guanidine product in an overall yield of 9% with a specific activity of 66 Ci mmol^{-1} . The final achievable specific activity could be improved by eliminating the use of non-radioactive iodomethane. This comes at the cost of increased handling associated with an extra chromatographic step. The final compound was suitable for *in vitro* and *in vivo* assessment of NMDA receptor function.

Experimental

General

All chemicals and solvents were obtained from Aldrich Chemical Co. (Milwaukee, WI) and were used without further purification. Solvents were dried by standard techniques. All reactions were performed under a nitrogen atmosphere. All NMR spectra were recorded using a Bruker DMX-300 MHz spectrometer at 320 MHz for ^3H . HPLC was carried out using a Waters 600E multisolvent delivery system with in-line UV monitoring of the effluent at 260 nm using a Hewlett Packard 1040A LC spectrometer and radioactivity detection using an in-line IN US beta RAM.

Tritium gas was procured from the Savannah River DOE complex and contained 98% $^3\text{H}_2$ and 2% $^2\text{H}^3\text{H}$. The purity of the reaction products was determined by radio-HPLC and ^3H NMR spectroscopy. The specific radioactivity of the tritiated products was determined by liquid scintillation counting (Packard Tricarb 1500) of the isolated HPLC peak effluents, as previously described.¹⁶ Proton and tritium NMR analyses were also used to verify the specific radioactivity of the product.

[$^3\text{H}_3$]methyl iodide. A solution of *n*-butyl lithium in hexane (1.6 M, 187 μl , 0.3 mmol) was rapidly stirred in the presence of an atmosphere of carrier-free tritium gas. Tetramethylethylenediamine (TMEDA) was added and after stirring for 20 min volatiles were removed. The residue was solvated with 500 μl THF followed by the addition of aluminum tribromide solution at ambient temperature (250 μl in 1 ml THF) to give LiAlT_4 . After 10 min carbon dioxide (1.5 ml) was injected and the reaction stirred for 3 h. Hydrogen iodide (57%; 150 μl) was added and the reaction heated to 170°C for 1 h then cooled to ambient temperature.

Preparation of N-[$^3\text{H}_3$]methyl-3-(thiomethylphenyl)cyanamide **2**. Tritiated iodomethane was distilled across to a flask containing an ice-cooled suspension of cyanamide **1** (2.8 mg, 0.017 mmol) and sodium hydride (0.8 mg, 0.033 mmol) in THF that had previously been heated to reflux for 3 h. The reaction was allowed to warm to ambient temperature and stirred overnight. Non-radioactive iodomethane (5 μl , 0.08 mmol in 200 μl THF) was then added to facilitate complete methylation. Methanol (100 μl) was added at 0°C to quench the reaction and the solvent removed under reduced pressure. The oil was transferred to an extraction tube using water (2 ml) and diethyl ether (10 ml). The ether was separated, dried (MgSO_4) and the solvent removed under a stream of nitrogen to give cyanamide **2** in 77% yield. $^3\text{H-NMR}$ (320 MHz; THF- d_8) δ [ppm] 3.21 (NC^3H_3 , s, 97% $^3\text{H}_3$, 2% $^3\text{H}_2^1\text{H}$ and 1% $^3\text{H}^1\text{H}_2$).

N-(2-chloro-5-methylthiophenyl)-*N'*-(3-methyl-thiophenyl)-*N'*-[$^3\text{H}_3$]methylguanidine **3**. A reaction vessel was charged with 825 mCi of the tertiary cyanamide **2**. To this was added an excess of aniline hydrochloride (20.8 mg, 0.098 mmol). A slurry was produced by the addition of 200 μl anhydrous chlorobenzene. The reaction was heated to 165°C for 24 h. The chlorobenzene was removed and the residue was dissolved in 1 ml of methanol. Purification of **3** was performed using two HPLC columns. Initial separation of **3** from **2** was carried out on a Zorbax CN (4.6 \times 250 mm; 65/35 methanol/0.1 N ammonium formate; flow rate 1.2 ml min $^{-1}$; t_r , **3** = 11 min, **2** = 6.25 min). The 11 min peak was collected, concentrated and then further purified using an HP Agilent LC-18 column (4.6 \times 250 mm; 65/35 methanol/0.1 N ammonium formate; flow rate 1 ml min $^{-1}$; t_r , **3** = 9 min). Lyophilization of the solvent gave 100 mCi of [$^3\text{H}_3$]CNS-5161, **3** (12% yield). The radiochemical purity of **3** was determined to be >96% by analytical HPLC (HP Agilent LC-18 column, 4.6 \times 250 mm; 65/35 methanol/0.1 N ammonium formate; flow rate 1 ml min $^{-1}$). $^3\text{H-NMR}$ (320 MHz; CD_3CN) δ [ppm] 3.28 (NC^3H_3 , s).

Acknowledgements

This work was supported by the Director of Lawrence Berkeley National Laboratory through the Laboratory Directed Research and Development Program (to AB) and by the Director, Office of Science,

Office of Biological and Environmental Research, Medical Science Division of the US Department of Energy under contract no. DE-AC03-76SF00098. The National Tritium Labelling Facility is supported by the Division of Biomedical Technology, National Center for Research Resources, US National Institutes of Health, under Grant P41 RR01237, through Department of Energy Contract DE-AC03-76SF00098 with the University of California.

References

1. Choi DW, Rothman SM. *Ann Rev Neurosci* 1990; **13**: 171–182.
2. Faden AI, DeMediuk P, Panter SS, Vink P. *Science* 1989; **244**: 798–800.
3. Greenamyre JT, Young AB. *Neurobiol Aging* 1989; **10**: 593–602.
4. Meldrum B, Garthwaite J. *Trends Pharmacol Sci* 1990; **11**: 379–387.
5. Morris RG, Anderson E, Lynch GS, Baudry M. *Nature* 1986; **319**: 774–776.
6. Olney JW. *Int Rev Neurobiol* 1985; **27**: 337–362.
7. Tamminga C. *Br J Psychiatry Suppl* 1999; **37**: 12–15.
8. Foster AC, Wong EH. *Br J Pharmacol* 1987; **91**: 403–409.
9. Price GW, Ahier RG, Middlemiss DN, Singh L, Tricklebank MD, Wong EHF. *Eur J Pharmacol* 1988; **158**: 279–282.
10. Wieland DM, Kilbourn MR, Yang DJ, *et al.* *Int J Rad Appl Instrum (Part A: Appl Radiat Isot)* 1988; **39**: 1219–1225.
11. Kiesewetter DO, Finn RD, Rice KC, Monn JA. *Int J Rad Appl Instrum (Part A: Appl Radiat Isot)* 1990; **41**: 139–142.
12. Ametamey SM, Samnick S, Leenders KL, *et al.* *J Recept Signal Transduct Res* 1999; **19**: 129–141.
13. Hu LY, Guo J, Magar SS, Fischer JB, Burke-Howie KJ, Durant GJ. *J Med Chem* 1997; **40**: 4281–4289.
14. Lee S, Morimoto H, Williams PG. *J Label Compd Radiopharm* 1997; **39**: 461–470.
15. Andres H, Morimoto H, Williams PG. *J Chem Soc Chem Commun* 1990; 627–628.
16. Than C, Morimoto H, Andres H, Williams PG. *J Label Compd Radiopharm* 1996; **38**: 693–711.